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Abstract
Background: Pelvic inflammatory disease (PID) is common and can lead to tubal factor infertility,
ectopic pregnancy or chronic pelvic pain. Despite major UK government investment in the National
Chlamydia Screening Programme, evidence of benefit remains controversial. The main aim of this
trial was to investigate whether screening and treatment of chlamydial infection reduced the
incidence of PID over 12 months. Secondary aims were to conduct exploratory studies of the role
of bacterial vaginosis (BV) in the development of PID and of the natural history of chlamydial
infection.
Design: Randomised controlled trial with follow up after 12 months.
Setting non-healthcare: Common rooms and lecture theatres at 20 universities and further
education colleges in Greater London.
Participants: 2500 sexually active female students were asked to complete a questionnaire on
sexual health and provide self-administered vaginal swabs and smears.
Intervention: Vaginal swabs from intervention women were tested for chlamydia by polymerase
chain reaction (PCR) and those infected referred for treatment. Vaginal swabs from control women
were stored and analysed after a year. Vaginal smears were Gram stained and analysed for BV.
Main outcome measure: Incidence of clinical PID over 12 months in intervention and control
groups. Possible cases of PID will be identified from questionnaires and record searches.
Confirmation of the diagnosis will be done by detailed review of medical records by three
independent researchers blind to whether the woman is in intervention or control group.
Trial registration: Clinical Trials NCT 00115388
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Pelvic inflammatory disease (PID) is the most important
preventable bacterial sexually transmitted infection in
industrialised countries[1]. Studies in clinical settings sug-
gest 15–50% of cases are caused by Chlamydia trachomatis
infection[1]. After one episode of PID around 15% of
women may become infertile, 10% suffer chronic pelvic
pain and 10% of subsequent pregnancies may be ectopic
which can be life threatening. The financial cost of treat-
ing PID and its sequelae, particularly tubal factor infertil-
ity, is considerable, quite apart from the emotional and
physical costs to the woman.
There has been only one major trial in non-pregnant
women of chlamydia screening to prevent PID[2]. This
was conducted over 15 years ago in an American popula-
tion using tests which have been superseded [2-4]. Before
chlamydial screening became widespread in the UK,
around 2006–2008, there was a window of opportunity
to conduct a trial of community based screening using
new nucleic acid amplification tests and non-invasive
screening in a young, multiethnic, female student popula-
tion[3].
In order to prevent chlamydia associated PID we also need
to understand more about the natural history of chlamy-
dial infection in women, and about the role of possible
co-factors such as bacterial vaginosis (BV). Studies to date
have been small[5] or cross-sectional[6], and a larger pro-
spective study is needed[3]. We developed a special
screening pack to test for chlamydia and BV using self-
administered vaginal swabs[7]. The method was accepta-
ble even during pregnancy and was used in our feasibility
study in a student bar recruiting women to a trial of
chlamydia screening[8]. The POPI (Prevention of Pelvic
Infection) trial should provide new information on the
effectiveness of screening for chlamydia, the possible role
of bacterial vaginosis, and the natural history of chlamy-
dial infection in the community.
Methods/Design
Primary aim
To investigate if screening young female students for
chlamydial infection and treating those found to be
infected reduces the incidence of PID in the subsequent
12 months.
Secondary aims
We will conduct exploratory studies to investigate:
1. The role of BV at baseline on the development of PID
over 12 months.
2. In women with untreated chlamydial infection, the
proportion who have persistent infection or develop PID
within 12 months.
3. The annual incidence of chlamydia infection in women
without chlamydia at baseline who return follow up
postal samples.
Design
Randomised controlled trial over one year
The flow of participants through the trial is shown in fig-
ure 1.
Setting
Common rooms, bars and lecture theatres at 20 universi-
ties and further education colleges in Greater London.
Following agreement from the Students' Union Presi-
dents, College Principals and welfare officers, posters
about the study were displayed on the Students' Union
website and notice boards. Recruitment was done by the
research general practitioner (GP) and female research
assistants assisted by trained peer recruiters as necessary.
Participants
Sexually experienced female students aged ≤ 27 years were
eligible for the study. Pregnant women, those who had
never been sexually active, women aged >27, and women
who had been tested for chlamydia in the past 3 months
were excluded.
Recruitment
Women considering taking part were given an informa-
tion leaflet and invited to discuss the study with the
research assistants or GP. Those who decided to partici-
pate were asked to sign a consent form, to complete a brief
confidential questionnaire on sexual health and behav-
iour, to provide self-administered vaginal swabs in the
nearest lavatory, and to consent to access to their medical
records for the purposes of this study.
The baseline questionnaire asked about risk factors for
chlamydial infection[9]: age, ethnicity, age at first sexual
intercourse, number of sexual partners in the past year,
contraceptive use; possible symptoms of infection: abnor-
mal vaginal discharge, pelvic pain, dyspareunia, inter-
menstrual or post-coital bleeding; recent antibiotic
treatment; history of sexually transmitted infection (STI);
vaginal douching, smoking and quality of life (EQ-5D).
To simplify recruitment, illustrated instructions on how to
provide a self-administered vaginal swab were printed on
specimen packs and displayed in the nearest lavatory, and
specimen containers were prelabelled[7].Page 2 of 6
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Design and timetable of trial of screening for chlamydia to prevent pelvic inflammatory disease (PID)Figure 1
Design and timetable of trial of screening for chlamydia to prevent pelvic inflammatory disease (PID).
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Within two weeks of recruitment participants were ran-
domly allocated into two groups by researchers at St
George's, University of London using random number
tables starting with a number at any position and going
consistently in any direction. Consecutive sealed speci-
men packs identified only by an ID number were taken
out of the large carrier bag into which they had been put
during recruitment sessions. If the random number ended
in 0–4 the pack was put into the intervention pile; if it
ended in 5–9 the pack was put into the control pile. Vagi-
nal swabs were taken out of the specimen packs in the
intervention pile and sent to the laboratory to be tested for
chlamydial infection by transcription mediated amplifica-
tion (TMA, Gen-Probe Incorporated San Diego, CA). Vag-
inal swabs from control women were stored at -80°C and
analysed one year later. Infected women were contacted as
soon as possible by the research GP and asked to attend
their local Genitourinary Medicine (GUM) Clinic or GP
for treatment and partner notification. One month later,
the research GP telephoned the women again to answer
any questions and to ensure that both they and their part-
ner(s) had completed a course of treatment.
Follow up after one year
A year after recruitment, participants were asked to com-
plete a secure online questionnaire about PID symptoms
during the previous 12 months. Those not responding or
not providing an email address were sent the question-
naire by post backed up by telephone reminders. In order
to maximise follow up, consent forms requested details of
home and term time addresses and telephone numbers,
email, mobile phone number, college course and GP
address. The questionnaire asked about possible symp-
toms of, or treatment for, PID or other STI, any additional
STI testing, and hospital and GP attendances in the past
year. Women who reported no symptoms of possible PID
on their questionnaire had no further follow up. For
women who did not return a questionnaire and those
who reported consulting a health professional for possi-
ble symptoms of PID we sent a questionnaire to their GPs.
This asked GPs to search both their records and any hos-
pital letters during the 12 month period after recruitment
for possible symptoms of PID. In addition, all women
who agreed on their follow up questionnaire to return a
further swab were sent one in the post. These postal sam-
ples were analysed immediately and infected women
referred for treatment.
Further analysis of vaginal samples
A year after recruitment we analysed stored baseline vagi-
nal swabs from women in the control group. Women
whose swabs were positive for chlamydia were referred to
GUM for retesting and treatment. Vaginal smears taken at
baseline were Gram stained and examined for BV using
Nugent's criteria[7]. Slides were read by two observers
who were blinded to each other's results, to characteristics
of participants and to outcome in terms of PID. Slides
were categorised as positive (Nugent score 7–10), inter-
mediate (4–6) or negative (0–3). Where the observers dis-
agreed, the slide was reviewed until consensus was
reached. There is little evidence that asymptomatic BV is
harmful in non-pregnant women and no treatment was
given. Participants worried about infection were advised
to have a check up.
Outcome measures
Primary outcome measure in the complete cohort
Incidence of clinical PID over 12 months in intervention
and control groups.
Possible cases of PID will be identified from patient and
GP 12 months questionnaires reporting pelvic infection,
abdominal or pelvic pain or dyspareunia. For women
who consulted a healthcare professional for these symp-
toms we will try to obtain clinical records including infor-
mation on symptoms, findings on examination and
laboratory results, excluding chlamydia results from trial
samples. We will also try to obtain details on any woman
reporting she had a laparoscopy in the follow up period.
Since it would be unethical to demand a laparoscopic
diagnosis of PID, as in the Scholes et al trial[2] we will use
a modified version of Hager's clinical criteria[10] where
details are provided in the medical records: lower abdom-
inal pain, adnexal tenderness and tenderness on cervical
motion. If available we will also include the results of con-
current microbiological tests and clinical data on fever
>38°, leucocytosis >10,000, purulent material or pelvic
abscess. To reduce bias, confirmation of the diagnosis will
be done by review of all data (anonymised questionnaires
and clinical records) by two independent GUM physicians
(with review by a third where they disagree) who will be
blind as to whether the patient is in intervention or con-
trol group.
Secondary outcome measures
We will conduct exploratory studies to investigate:
1. The role of BV at baseline on the development of PID
over 12 months.
2. In women with untreated chlamydial infection, the
proportion who have persistent infection or develop PID
within 12 months.
3. The annual incidence of chlamydia infection in women
without chlamydia at baseline who return follow up
postal samples,Page 4 of 6
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The GU physicians will be blind to group assignment.
They will categorise cases of PID as probable, possible or
not PID, for example if subsequent laparoscopy suggests
the pain is due to endometriosis. The research assistant
who selected the questionnaires and anonymised the
medical records for assessment for possible PID was also
blind to study group assignment.
All participants were blind except those in the interven-
tion group whose baseline samples were positive for
chlamydia and who were referred for treatment. It is pos-
sible that the principle investigator who contacted women
to tell them they were chlamydia positive might remem-
ber some names when assisting with obtaining medical
records for follow up 1–2 years later. There was a change
of research assistant between recruitment and final follow
up. The research assistant doing the final follow up for
PID diagnosis was not involved in randomization or test-
ing and treatment of chlamydia positives. Both she and
the PI had access to group allocation but avoided looking
at this during follow up.
Sample size calculations
Assuming a 2% incidence of PID, a sample size of 4122
women would allow a relative risk (RR) of 0.48 to be
detected with 80% power using a 5% significance level.
This was based on data from the Scholes et al trial[2]
where the rate of chlamydia was 7%. Assuming 20% of
women were lost to follow up, we would have needed to
recruit 5000 women.
However we had great difficulties with recruitment, and a
publication in 2004 suggested a higher rate of PID[11]
enabling us to revise down our sample size calculations. If
we assume a 3% incidence of PID in the control
group[11,12], we would need a sample of 2274 women to
detect a RR of 0.44% with 80% power and 5% signifi-
cance. Details on the consent form provided up to 7
potential contact methods for follow up, and we achieved
92% follow up after 8 months in the feasibility study[8].
To reduce bias we aimed to keep loss to follow up at 12
months below 10%. Assuming 10% loss to follow up we
needed to recruit 2501 women.
Analysis Plan
For the primary analysis, we will estimate the relative risk
of developing PID in the 12 months after recruitment in
the intervention group compared with the control.
In secondary analyses, we will conduct an exploratory
logistic regression to adjust the RR of development of PID
for the presence of baseline BV.
We will conduct further exploratory analyses to assess:
In women with untreated chlamydial infection, the pro-
portion (95%CI) who have persistent infection or
develop PID within 12 months.
The annual incidence (95%CI) of chlamydia infection in
women without chlamydia at baseline who return follow
up postal samples.
Ethical issues
The POPI trial was approved by Wandsworth Research
Ethics Committee in 2003 (Ref 03.0054). The main ethi-
cal issue was that samples from control women were
stored and not tested for chlamydia for 12 months. This
was clearly explained to the women before they partici-
pated and repeated on the information sheet and consent
form (attached). In addition an extra copy of the informa-
tion sheet was posted to their home address. The patient
information leaflet (please see additional file 1) stated:
"What are the risks of taking part? When you sign the con-
sent form you should note that your vaginal sample will
be tested for a sexually transmitted infection called
chlamydia. However the test may not be done for a whole
year. You could have chlamydial infection without experi-
encing any symptoms. This could lead to pelvic inflam-
matory disease with a risk that you have chronic pelvic
pain, become infertile, or that if you become pregnant
that you have an ectopic pregnancy (a pregnancy in a fal-
lopian tube which can be fatal). This is why if you could have
been at risk of infection, or have any symptoms which could be
due to a sexually transmitted infection, it is vital that you have
a check up at a genitourinary clinic even if you are participating
in the study".
Discussion
Recruiting young women to a trial of chlamydia screening
proved much harder than anticipated. We developed new
techniques to market the trial to students, particularly
recruiting from lectures and offering lollipops[13,14]. To
achieve our sample size we also had to extend recruitment
to 20 educational institutions and to prolong the recruit-
ment period to 2 years (from September 2004 to October
2006.) For the first 4 months of recruitment, peer recruit-
ers completed response rate forms. Of 2323 women
approached 41% (956) were ineligible: 41% (n = 390)
had never had sexual intercourse, 24% were aged <16 (n
= 19) or >27 years (n = 206), and 14% (n = 136) had been
tested for chlamydia in the previous 3 months. The
response rate in those eligible was 32% (440/1367). Rea-
sons for refusal (n = 927) included "not interested" 35%,
"too busy" 31%, "don't want to provide swab" 13%.
Recruitment rates seemed to improve later in the trial and
were over 60% in the last three sessions[14].Page 5 of 6
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Conclusion
The trial will be the first to show if screening for chlamy-
dial infection can reduce the incidence of PID in a British
population. It will also show if non-invasive screening of
high risk, difficult to access groups such as women aged
<20 and those from black ethnic minorities is feasible out-
side health care settings. Over 40% of young people in the
UK now attend higher education adding to the generalis-
ability of the results. If the intervention is effective,
extending such screening programmes to the community
should help to reduce the burden of PID. Finally by pro-
viding new information on both the effectiveness of
screening and on the natural history of chlamydial infec-
tion and the influence of BV, the study will contribute to
the evidence base for the UK National Strategy for Sexual
Health. The trial will report in December 2008.
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